Integration of antiretroviral therapy with tuberculosis treatment

New England Journal of Medicine

Volumn 365, Issue 16, 2011, Pages 1492-1501

  Abdool Karim, Salim S ^a,b,c   Naidoo, Kogieleum ^a   Grobler, Anneke ^a   Padayatchi, Nesri ^a,b   Baxter, Cheryl ^a   Gray, Andrew L ^b   Gengiah, Tanuja ^a   Gengiah, Santhanalakshmi ^a   Naidoo, Anushka ^a   Jithoo, Niraksha ^a   Nair, Gonasagrie ^a   El Sadr, Wafaa M ^c   Friedland, Gerald ^d   Abdool Karim, Quarraisha ^a,b,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c Columbia University ^*  (United States)

^d YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN;

ACID FAST BACTERIUM; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; SPUTUM SMEAR; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 80054720851     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1014181     Document Type: Article

References (16)

1. Fishman JE, Saraf-Lavi E, Narita M, Hollender ES, Ramsinghani R, Ashkin D. Pulmonary tuberculosis in AIDS participants: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000;174:43-9. (Pubitemid 30030205)
2. Chien JW, Johnson JL. Paradoxical reactions in HIV and pulmonary TB. Chest 1998;114:933-6. (Pubitemid 28433762)
3. Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:326-31. (Pubitemid 32435996)
4. Lalloo UG. Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas? Clin Infect Dis 2009;48:1760-2.
5. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009;14:687-95.
6. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
7. The South African National Tuberculosis Control Programme: practical guidelines 2004. Pretoria: South African Department of Health, 2004.
8. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization, 2009.
9. Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81.
10. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365:1482-91.
11. Shao HJ, Crump JA, Ramadhani HO, et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses 2009;25:1277-85.
12. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007;21:335-41. (Pubitemid 46175045)
13. Sharma SK, Dhooria S, Barwad P, et al. A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res 2010;131:804-8.
14. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002;16:75-83. (Pubitemid 34062184)
15. Tansuphasawadikul S, Saito W, Kim J, et al. Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. Southeast Asian J Trop Med Public Health 2007;38:1053-60.
16. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009;20:339-45.